Human Mousavi Fatemi
Overview
Explore the profile of Human Mousavi Fatemi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azargoon A, Fatemi H, Mirmohammadkhani M, Darzi S
J Family Reprod Health
. 2023 Aug;
17(1):21-28.
PMID: 37538230
Objective: This study aimed to compare the effects of clomiphene citrate (CC) combined with metformin or placebo on infertile patients with poly cystic ovary syndrome (PCOS) and insulin resistance (IR)....
2.
De Munck N, Bayram A, Elkhatib I, Abdala A, El-Damen A, Arnanz A, et al.
PLoS One
. 2022 Apr;
17(4):e0267241.
PMID: 35468159
Objective: This study aimed to analyze the morphokinetic behaviour between conventional IVF and ICSI, in cycles with preimplantation genetic testing for aneuploidies (PGT-A). Materials: A randomized controlled trial (NCT03708991) was...
3.
Melado L, Arnanz A, Bayram A, Elkhatib I, De Munck N, Navarro A, et al.
Reprod Biomed Online
. 2020 Jun;
41(1):119-127.
PMID: 32499103
Research Question: This study explored the relationship between anti-Müllerian hormone (AMH) and oocyte survival after vitrification. The association between AMH and blastocyst formation after oocyte vitrification was also assessed. Design:...
4.
Melado L, Lawrenz B, Sibal J, Abu E, Coughlan C, Navarro A, et al.
Front Endocrinol (Lausanne)
. 2018 Dec;
9:686.
PMID: 30542322
Anti-Müllerian hormone (AMH) is an important ovarian reserve marker for baseline assessment and therapeutic strategy in fertility treatments, which is considered reliable when measured on any day of the cycle....
5.
Lawrenz B, Mahajan N, Fatemi H
Future Oncol
. 2016 Mar;
12(14):1721-9.
PMID: 26956228
Due to the improvements of cancer treatment, the survival rate of cancer increased over the last decades. One of the detrimental side effects of cytotoxic treatment is the impairment or...
6.
Gurbuz A, Deveer R, Ozcimen N, Ozcimen E, Lawrenz B, Banker M, et al.
Gynecol Endocrinol
. 2015 Oct;
32(1):18-20.
PMID: 26487486
Human chorionic gonadotropin (hCG) is commonly used for final oocyte maturation in "in vitro fertilization" (IVF)-treatment cycles, however, the main important risk is development of severe ovarian hyperstimulation syndrome (OHSS)....
7.
Fatemi H, Garcia-Velasco J
Fertil Steril
. 2015 Mar;
103(4):870-3.
PMID: 25724740
Ovarian hyperstimulation syndrome (OHSS) is one of the most serious, and potentially lethal, complications of controlled ovarian stimulation (COS). Induction of final oocyte maturation with a bolus of gonadotropin-releasing hormone...
8.
Fatemi H, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al.
Fertil Steril
. 2014 Feb;
101(4):1008-11.
PMID: 24534283
Objective: To report two cases with GnRH agonist triggering and a freeze-all approach in a GnRH antagonist protocol resulting in the development of severe ovarian hyperstimulation syndrome (OHSS), requiring hospitalization...
9.
Van Vaerenbergh I, Blockeel C, Van Lommel L, Ghislain V, Int Veld P, Schuit F, et al.
Fertil Steril
. 2010 Aug;
95(1):448-51, 451.e1-2.
PMID: 20800227
The gene expression of human endometrium on the day of oocyte retrieval of pregnant and nonpregnant patients in a stimulated IVF cycle was compared in two independent groups with different...
10.
Blockeel C, Van Vaerenbergh I, Fatemi H, Van Lommel L, Devroey P, Bourgain C
Mol Hum Reprod
. 2010 Aug;
17(1):33-41.
PMID: 20705718
The past decade has seen growing interest in ovarian stimulation protocols with GnRH antagonists in an effort to reduce the incidence of potential complications, such as cyst formation and ovarian...